Technical Analysis for STRO - Sutro Biopharma, Inc.

Grade Last Price % Change Price Change
grade D 11.03 -2.99% -0.34
STRO closed down 2.99 percent on Wednesday, July 17, 2019, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical STRO trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Golden Cross Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish -2.99%

Older signals for STRO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Medicine Cancer Clinical Medicine Immunology California Antibodies Drug Discovery Cancer Treatments Antineoplastic Drugs Multiple Myeloma Sutro Biopharma Autoimmune Disorders Non Hodgkin Lymphoma Adc Immunogen South San Francisco Therapeutics For Cancer Milatuzumab
Is STRO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.9
52 Week Low 8.5
Average Volume 44,641
200-Day Moving Average 11.2037
50-Day Moving Average 11.235
20-Day Moving Average 11.5305
10-Day Moving Average 11.434
Average True Range 0.5562
ADX 10.44
+DI 12.1785
-DI 18.1104
Chandelier Exit (Long, 3 ATRs ) 10.8214
Chandelier Exit (Short, 3 ATRs ) 12.5686
Upper Bollinger Band 11.9461
Lower Bollinger Band 11.1149
Percent B (%b) -0.1
BandWidth 7.208707
MACD Line -0.0015
MACD Signal Line 0.0648
MACD Histogram -0.0663
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.71
Resistance 3 (R3) 11.78 11.63 11.59
Resistance 2 (R2) 11.63 11.46 11.59 11.55
Resistance 1 (R1) 11.33 11.35 11.26 11.26 11.52
Pivot Point 11.18 11.18 11.14 11.14 11.18
Support 1 (S1) 10.88 11.01 10.81 10.81 10.54
Support 2 (S2) 10.73 10.90 10.69 10.51
Support 3 (S3) 10.43 10.73 10.47
Support 4 (S4) 10.36